Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benralizumab - Kyowa Kirin/MedImmune

Drug Profile

Benralizumab - Kyowa Kirin/MedImmune

Alternative Names: Benra; BIW-8405; BIW-8405-IL-5R; Fasenra; KHK 4563; MEDI-563

Latest Information Update: 11 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioWa
  • Developer AstraZeneca; Cincinnati Children's Hospital Medical Center; Kyowa Hakko; Kyowa Kirin; McMaster University; MedImmune; National Jewish Medical and Research Center
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Apoptosis stimulants; Interleukin-5 receptor alpha subunit inhibitors; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypereosinophilic syndrome; Churg-Strauss syndrome; Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Phase III Chronic obstructive pulmonary disease; Nasal polyps
  • Phase II Atopic dermatitis; Churg-Strauss syndrome; Hypereosinophilic syndrome; Rhinosinusitis
  • Phase I/II Eosinophilic gastroenteritis
  • Clinical Phase Unknown Skin disorders

Most Recent Events

  • 04 Oct 2019 The EMA approves self-administered benralizumab pre-filled, single-use auto-injector (Fasenra pen) for Asthma before October 2019
  • 04 Oct 2019 The US FDA approves self-administered benralizumab pre-filled, single-use auto-injector (Fasenra pen) for Asthma
  • 30 Sep 2019 New pooled efficacy data from the phase III GALATHEA and TERRANOVA trials in Chronic obstructive pulmonary disease released by AstraZeneca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top